Paper Details
- Home
- Paper Details
Levodopa Equivalent Dose of Safinamide: A Multicenter, Longitudinal, Case-Control Study.
Author: BelliniGabriele, BonvegnaSalvatore, BracciaArianna, BrighinaLaura, BrovelliFrancesco, CanesiMargherita, CeravoloRoberto, CeredaEmanuele, CeredaViviana, CiliaRoberto, ColucciFabiana, ContaldiElena, De MiccoRosa, GelosaGiorgio, Golfrè AndreasiNico, ImbalzanoGabriele, LazzeriGiulia, MagistrelliLuca, ManciniFrancesca, MeloniMario, ModugnoNicola, OlivolaEnrica, PacchettiClaudio, PellecchiaMaria Teresa, PiattiMarco, PilottoAndrea, PintoPatrizia, PistoiaFrancesca, RussilloMaria Claudia, SensiMariachiara, SessaMaria, SorberaChiara, SucapanePatrizia, ZangagliaRoberta
Original Abstract of the Article :
Effects of dopaminergic medications used to treat Parkinson's disease (PD) may be compared with each other by using conversion factors, calculated as Levodopa equivalent dose (LED). However, current LED proposals on MAO-B inhibitors (iMAO-B) safinamide and rasagiline are still based on empirical app...See full text at original site
Dr.Camel's Paper Summary Blogラクダ博士について
ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。
* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。
引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10105110/
データ提供：米国国立医学図書館（NLM）
Levodopa Equivalent Dose of Safinamide: A New Approach to Comparing Dopaminergic Medications
This study delves into the field of [Parkinson's disease] treatment, seeking to improve the understanding and comparison of different dopaminergic medications. Imagine a desert marketplace where different merchants offer various remedies for Parkinson's disease. The study focuses on safinamide, an MAO-B inhibitor, and aims to establish a reliable method for comparing its effects to those of levodopa, a commonly used medication for Parkinson's disease.
A Standardized Approach to Medication Comparison
The study proposes a new approach to comparing dopaminergic medications by using conversion factors, calculated as Levodopa equivalent dose (LED). This standardized approach, like a universal translator in the desert marketplace, allows researchers and clinicians to better understand the relative effectiveness of different medications. The study aims to develop a more accurate and reliable LED proposal for safinamide, providing a clearer picture of its therapeutic value.
Improving Parkinson's Disease Management
This research has the potential to improve the management of Parkinson's disease. By developing a more accurate LED for safinamide, clinicians can make more informed decisions about treatment options, ensuring optimal care for their patients. It's like a desert guide using a map to navigate the complex terrain of Parkinson's disease treatment, ensuring a safe and effective journey for their patients.
Dr.Camel's Conclusion
This research presents a new and innovative approach to comparing dopaminergic medications for Parkinson's disease. By establishing a more precise LED for safinamide, clinicians can navigate the diverse landscape of treatment options with greater confidence, leading to better outcomes for their patients.
Date :
- Date Completed n.d.
- Date Revised 2023-04-19
Further Info :
Related Literature
English
This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.